Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9fdcacb958e135c4710becdc4f6fc98f |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70539 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
filingDate |
2020-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3df3a81a48f47ad793a22eca22789a10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_852013ea725cad0805b7c4ce3f9a883c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93043779522587817e8a7ac44b441ad0 |
publicationDate |
2022-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CN-114381469-A |
titleOfInvention |
Carrier fragment for chimeric MHC (major histocompatibility complex) and autoantigen and application thereof |
abstract |
The invention discloses a carrier fragment for chimeric MHC (major histocompatibility complex) and autoantigen and application thereof. The vector fragment contains a cDNA sequence of an HLA gene, a gene expressing an autoantigen and a gene expressing an intracellular activation domain sequence. The invention constructs expression vector segments of various chimeric MHC-polypeptide antigens, and can express the structure of the chimeric MHC-polypeptide on the surface of an effector T cell in a current especially mature lentiviral vector mode, so that the effector T cell can present autoantigen peptide through the chimeric MHC, the TCR of the autoreactive T cell is identified by the structural specificity of the chimeric MHC-polypeptide, and the autoreactive T cell is further subjected to specific killing and clearing so as to achieve the effect of treating autoimmune diseases. |
priorityDate |
2020-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |